Kezar Life Sciences, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (6)

Latest Posts

About This Stock More About This Stock
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
Article By: ChinaBio® Today
Saturday, March 2, 2024 2:00 PM EDT
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global rights for Roxadustat to FibroGen.
In this article: AZN, TEVA, FGEN, KZR, IVBXF, IRON
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
Article By: ChinaBio® Today
Saturday, September 23, 2023 2:19 PM EDT
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make an upfront payment of $7 million to Kezar.
In this article: NVS, BGNE, KZR Also: BMY, OCUL
The Week In Charts: How To Make Money While Waiting For Core Trend Trades
Video By: Dave Landry
Saturday, July 2, 2022 9:03 PM EDT
The real money is in the longer-term core trend trades. However, sometimes those opportunities can be few and far between. This is especially true in a bear market.
In this video: BLU, DIG, HTHT, KZR, TCOM, WYNN

Latest Tweets for $KZR

No tweets yet!